Hsbc Holdings PLC Kodiak Sciences Inc. Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 42,645 shares of KOD stock, worth $373,143. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,645

Previous 42,171 1.12%

Holding current value

$373,143

Previous $99,000 12.12%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.2 - $3.25 $1,042 - $1,540	474 Added 1.12%	42,645 $111,000
Q2 2024 Aug 12, 2024	BUY	$2.29 - $4.48 $4,225 - $8,265	1,845 Added 4.58%	42,171 $99,000
Q1 2024 May 15, 2024	SELL	$3.01 - $7.45 $1,489 - $3,687	-495 Reduced 1.21%	40,326 $212,000
Q4 2023 Feb 12, 2024	BUY	$1.4 - $3.24 $36 - $84	26 Added 0.06%	40,821 $124,000
Q3 2023 Nov 13, 2023	BUY	$1.8 - $7.49 $45,095 - $187,646	25,053 Added 159.15%	40,795 $73,000
Q2 2023 Aug 11, 2023	SELL	$4.3 - $9.48 $55,912 - $123,268	-13,003 Reduced 45.24%	15,742 $108,000
Q1 2023 May 15, 2023	BUY	$4.81 - $8.88 $6,089 - $11,242	1,266 Added 4.61%	28,745 $178,000
Q4 2022 Feb 14, 2023	BUY	$6.52 - $8.05 $6,376 - $7,872	978 Added 3.69%	27,479 $196,000
Q3 2022 Nov 14, 2022	SELL	$7.57 - $12.5 $31,877 - $52,637	-4,211 Reduced 13.71%	26,501 $208,000
Q2 2022 Aug 11, 2022	SELL	$5.04 - $9.48 $2,444 - $4,597	-485 Reduced 1.55%	30,712 $239,000
Q1 2022 May 16, 2022	BUY	$7.09 - $89.45 $221,186 - $2.79 Million	31,197 New	31,197 $240,000

Others Institutions Holding KOD

# of Institutions

Shares Held

39M

Call Options Held

6.5K

Put Options Held

5.8K

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Kodiak Sciences Inc. Transaction History